摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4t-(5-acetyl-3-ethoxycarbonyl-6-oxo-6H-pyran-2-yl)-2-((Z)-1-hydroxy-ethylidene)-but-3-enoic acid ethyl ester | 112158-11-9

中文名称
——
中文别名
——
英文名称
4t-(5-acetyl-3-ethoxycarbonyl-6-oxo-6H-pyran-2-yl)-2-((Z)-1-hydroxy-ethylidene)-but-3-enoic acid ethyl ester
英文别名
4t-(5-acetyl-3-ethoxycarbonyl-6-oxo-6H-pyran-2-yl)-2-((Z)-1-hydroxy-ethylidene)-but-3-enoic acid ethyl ester;4t-(5-Acetyl-3-aethoxycarbonyl-6-oxo-6H-pyran-2-yl)-2-((Z)-1-hydroxy-aethyliden)-but-3-ensaeure-aethylester
4t-(5-acetyl-3-ethoxycarbonyl-6-oxo-6H-pyran-2-yl)-2-((Z)-1-hydroxy-ethylidene)-but-3-enoic acid ethyl ester化学式
CAS
112158-11-9
化学式
C18H20O8
mdl
——
分子量
364.352
InChiKey
YMOAVDRPQGYJAW-YZDDFNNUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    495.9±45.0 °C(Predicted)
  • 密度:
    1.336±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.43
  • 重原子数:
    26.0
  • 可旋转键数:
    7.0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    120.11
  • 氢给体数:
    1.0
  • 氢受体数:
    8.0

反应信息

点击查看最新优质反应信息

文献信息

  • Polyketo-enols and chelates. Part IV. The by-product in the xanthophanic–glaucophanic enol reaction: 2-acetyl-4,7-alkoxycarbonyl-1,6-dimethylnaphthalane
    作者:L. Crombie、D. E. Games、M. H. Knight
    DOI:10.1039/j39670000777
    日期:——
    The by-product described in the title is shown to be 2-acetyl-4,7-diethoxycarbonyl-1,6-dimethylnaphthalene by hydrolysis and decarboxylation to 2-acetyl-1,6-dimethylnaphthalene. Since the 1,6-relationship of the methyls is known the acetyl was degraded to a methyl group via a haloform reaction, metal hydride reduction, and hydrogenolysis. The product was shown to be 1,2,6-trimethylnaphthalene by side-chain
    通过解和脱羧成2-乙酰基-1,6-二甲基萘,标题中所述的副产物显示为2-乙酰基-4,7-二乙氧基羰基-1,6-二甲基萘。因为已知甲基的1,6-关系,所以乙酰基通过卤仿反应,氢化物还原和氢解被降解为甲基。通过侧链三化显示产物为1,2,6-三甲基萘,得到1,2,6-三甲基萘,与真实样品相同,与1,4,6-三甲基萘不同。考虑的来源。
  • Triple Marker Screening for Trisomy 21, Trisomy 18 and Open Neural Tube Defects in Singleton Pregnancies of Native Japanese Pregnant Women
    作者:Takekazu Onda、Tadao Tanaka、Koyo Yoshida、Yasushi Nakamura、Ryuichi Kudo、Hiroyuki Yamamoto、Akira Sato、Kaoru Yanagida、Yasushi Takai、Hiraku Uemura、Kazuhiko Hoshi、Yukihito Fukada、Yoshiaki Miyake、Miyako Ohnishi、Tsuyoshi Kaneoka、Yasuo Makino、Yuji Murata、Toru Kanzaki、Hideharu Kanzaki、Takashi Osaki、Toshihiro Aono、Kazuhisa Maeda、Sachio Ogita、Seiichi Yamamasu、Takeshi Aso、Yasufumi Shimizu、Toshihiko Izutsu、Tomohiko Kudo、Takashi Okai、Masato Sakai、Toshirou Hashimoto、Noboru Matsuzaki、Michihiro Kitagawa、Haruhiko Sago、Robert E. Grier、Faye Myrick
    DOI:10.1111/j.1447-0756.2000.tb01355.x
    日期:2000.12
    AbstractObjective: To report the results of prenatal triple marker screening on a population of Japanese pregnant women.Methods: From April 1994 through March 1999, a total of 32,925 native Japanese women with singleton pregnancies requested a triple marker‐screening test. Multiples of the median values for 3 markers and individual risks for each patient were calculated following adjustment for the Japanese weight correction factor. The risk cut‐off values used for Down syndrome (T21), open spina bifida (OSB) and trisomy 18 (T18) were 1:295, 1:290, and 1:100, respectively. Follow‐up information was collected postpartum and statistically analyzed.Results: Detection rates (DR) of T21 for women less than 35 years, over 35 years and overall were 58, 94, and 83%, respectively. DR of T18 for women less than 35 years, over 35 years and overall were 75, 79, and 79%, respectively. DR of open neural tube defects (ONTD) was 100%.Conclusions: The first cumulative data of an intervention program and prospective follow‐up studies in Japan have proven to be similar to other published reports. Individual risk values were calculated for each pregnancy for T21, T18 and ONTD. This screening program is more effective than age‐dependent screening for detecting T21, T18 and ONTD pregnancies.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸